Guangming Daily Beijing, December 4, reporter Qi Fang recently learned from the Institute of Microbiology of the Chinese Academy of Sciences that JS016, a new drug with independent intellectual property rights of new crown pneumonia therapeutic antibodies, has completed the international multi-center Phase II clinical trial and is actively promoting Phase III clinical trials.
Yan Jinghua, the main developer of this drug and a researcher at the Institute of Microbiology of the Chinese Academy of Sciences, introduced that JS016 is an injectable drug jointly developed by the institute and Shanghai Junshi Biology, and the generic name is "ettexvirumab".
Yan Jinghua introduced that this single antibody drug comes from the memory B cells of patients who have recovered from the new crown, "This memory B cell can produce antibodies to the new crown virus." We obtain this antibody gene using single-cell sequencing, then clone it in vitro and cell expression, purify it, and then transfuse it back into the patient's body to play a therapeutic role."
"For a virus to invade a cell, it needs a protein on its surface to interact with a protein on the body's cell. If we liken this process to 'opening a door,' then these two interacting proteins are keys and locks. Yan Jinghua explained, "And antibodies can block this interaction, as if the key is blindfolded, and the virus can no longer invade the cell." ”
JS016 has also gained worldwide attention. Junshi Biotech partnered with Eli Lilly to authorize commercial development in markets outside of Greater China. Eli Lilly conducted several Phase III clinical trials of JS016 antibody in combination with another monoclonal antibody in its own, and the results showed that for mild to moderate COVID-19 patients at high risk of severe illness, combination therapy can significantly reduce the risk of hospitalization and all-cause death events (70% to 84%), and protect death cases by 100%. The combination therapy has been authorized for emergency use in 15 countries and regions, including the United States, the European Union, India, and Brazil, and is one of the three covid-19 antibody therapies currently used internationally. Recently, the US FDA has expanded the use of the combination antibody and approved it for emergency prevention after new crown exposure, and the US government has purchased more than 900,000 doses for many times, and the European Union has purchased 220,000 doses for post-exposure prevention of new crown and the treatment of mild and ordinary patients. More than 500,000 people have received the JS016 combination therapy, according to OurWorldinData, the current CASE fatality rate of COVID-19 is 2.01%, and the use of 500,000 doses of the drug may have averted nearly 10,000 deaths.
Yan Jinghua said: "At present, there have been many important advances in global COVID-19 drug research and development, and the combination of multiple targets will be an option for treating people infected with the new crown virus in the future, until we finally defeat the virus." ”
Guangming Daily ( 03/12/2021)
Source: Guangming Network - Guangming Daily
![An article teaches you to use JS+CSS to implement a simple loading progress bar effect one, preface two, project preparation three, project realization four, effect display five, summary[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)